APO RESEARCH · REPORT
Microbiome Drugs
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
Product & engineering
Understand the product.
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
Selected research
Industry Research
Microbiome Drugs Industry Research Report 2026
Market perspective
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.
Report Scope
Read the full market overview
This report quantifies the global Microbiome Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Microbiome Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Microbiome Drugs Market by Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
Rebiotix
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Osel
Microbiome Drugs Segment by Type
Oral Dosage Form
Enteric Capsules
Microbiome Drugs Segment by Symptom
Gastrointestinal Disorders
Autoimmune Disorders
Diabetes
Cancer
Others
Microbiome Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Dosage Form
- Enteric Capsules
Applications
- Gastrointestinal Disorders
- Autoimmune Disorders
- Diabetes
- Cancer
- Others
Companies covered
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- Rebiotix
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Osel
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Microbiome Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral Dosage Form
- 2.2.3 Enteric Capsules
- 2.3 Microbiome Drugs by Symptom
- 2.3.1 Market Value Comparison by Symptom (2021 VS 2025 VS 2032)
- 2.3.2 Gastrointestinal Disorders
- 2.3.3 Autoimmune Disorders
- 2.3.4 Diabetes
- 2.3.5 Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Microbiome Drugs Breakdown Data by Type
- 3.1 Global Microbiome Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Microbiome Drugs Forecasted Market Size by Type (2027-2032)
4 Microbiome Drugs Breakdown Data by Symptom
- 4.1 Global Microbiome Drugs Historic Market Size by Symptom (2021-2026)
- 4.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2027-2032)
5 Global Growth Trends
- 5.1 Global Microbiome Drugs Market Perspective (2021-2032)
- 5.2 Global Microbiome Drugs Growth Trends by Region
- 5.2.1 Global Microbiome Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Microbiome Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Microbiome Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Microbiome Drugs Market Dynamics
- 5.3.1 Microbiome Drugs Industry Trends
- 5.3.2 Microbiome Drugs Market Drivers
- 5.3.3 Microbiome Drugs Market Challenges
- 5.3.4 Microbiome Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Microbiome Drugs Players by Revenue
- 6.1.1 Global Top Microbiome Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Microbiome Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Microbiome Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Microbiome Drugs Head Office and Area Served
- 6.4 Global Microbiome Drugs Players, Product Type & Application
- 6.5 Global Microbiome Drugs Manufacturers Established Date
- 6.6 Global Microbiome Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Microbiome Drugs Market Size (2021-2032)
- 7.2 North America Microbiome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Microbiome Drugs Market Size by Country (2021-2026)
- 7.4 North America Microbiome Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Microbiome Drugs Market Size (2021-2032)
- 8.2 Europe Microbiome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Microbiome Drugs Market Size by Country (2021-2026)
- 8.4 Europe Microbiome Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Microbiome Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Microbiome Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Microbiome Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Microbiome Drugs Market Size (2021-2032)
- 10.2 South America Microbiome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Microbiome Drugs Market Size by Country (2021-2026)
- 10.4 South America Microbiome Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Microbiome Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Microbiome Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Microbiome Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Seres Therapeutics
- 12.1.1 Seres Therapeutics Company Information
- 12.1.2 Seres Therapeutics Business Overview
- 12.1.3 Seres Therapeutics Revenue in Microbiome Drugs Business (2021-2026)
- 12.1.4 Seres Therapeutics Microbiome Drugs Product Portfolio
- 12.1.5 Seres Therapeutics Recent Developments
- 12.2 Assembly Biosciences
- 12.2.1 Assembly Biosciences Company Information
- 12.2.2 Assembly Biosciences Business Overview
- 12.2.3 Assembly Biosciences Revenue in Microbiome Drugs Business (2021-2026)
- 12.2.4 Assembly Biosciences Microbiome Drugs Product Portfolio
- 12.2.5 Assembly Biosciences Recent Developments
- 12.3 Synthetic Biologics
- 12.3.1 Synthetic Biologics Company Information
- 12.3.2 Synthetic Biologics Business Overview
- 12.3.3 Synthetic Biologics Revenue in Microbiome Drugs Business (2021-2026)
- 12.3.4 Synthetic Biologics Microbiome Drugs Product Portfolio
- 12.3.5 Synthetic Biologics Recent Developments
- 12.4 Interxon
- 12.4.1 Interxon Company Information
- 12.4.2 Interxon Business Overview
- 12.4.3 Interxon Revenue in Microbiome Drugs Business (2021-2026)
- 12.4.4 Interxon Microbiome Drugs Product Portfolio
- 12.4.5 Interxon Recent Developments
- 12.5 PureTech
- 12.5.1 PureTech Company Information
- 12.5.2 PureTech Business Overview
- 12.5.3 PureTech Revenue in Microbiome Drugs Business (2021-2026)
- 12.5.4 PureTech Microbiome Drugs Product Portfolio
- 12.5.5 PureTech Recent Developments
- 12.6 Synlogic
- 12.6.1 Synlogic Company Information
- 12.6.2 Synlogic Business Overview
- 12.6.3 Synlogic Revenue in Microbiome Drugs Business (2021-2026)
- 12.6.4 Synlogic Microbiome Drugs Product Portfolio
- 12.6.5 Synlogic Recent Developments
- 12.7 Enterome BioScience
- 12.7.1 Enterome BioScience Company Information
- 12.7.2 Enterome BioScience Business Overview
- 12.7.3 Enterome BioScience Revenue in Microbiome Drugs Business (2021-2026)
- 12.7.4 Enterome BioScience Microbiome Drugs Product Portfolio
- 12.7.5 Enterome BioScience Recent Developments
- 12.8 4D Pharma
- 12.8.1 4D Pharma Company Information
- 12.8.2 4D Pharma Business Overview
- 12.8.3 4D Pharma Revenue in Microbiome Drugs Business (2021-2026)
- 12.8.4 4D Pharma Microbiome Drugs Product Portfolio
- 12.8.5 4D Pharma Recent Developments
- 12.9 Second Genome
- 12.9.1 Second Genome Company Information
- 12.9.2 Second Genome Business Overview
- 12.9.3 Second Genome Revenue in Microbiome Drugs Business (2021-2026)
- 12.9.4 Second Genome Microbiome Drugs Product Portfolio
- 12.9.5 Second Genome Recent Developments
- 12.10 AOBiome
- 12.10.1 AOBiome Company Information
- 12.10.2 AOBiome Business Overview
- 12.10.3 AOBiome Revenue in Microbiome Drugs Business (2021-2026)
- 12.10.4 AOBiome Microbiome Drugs Product Portfolio
- 12.10.5 AOBiome Recent Developments
- 12.11 Rebiotix
- 12.11.1 Rebiotix Company Information
- 12.11.2 Rebiotix Business Overview
- 12.11.3 Rebiotix Revenue in Microbiome Drugs Business (2021-2026)
- 12.11.4 Rebiotix Microbiome Drugs Product Portfolio
- 12.11.5 Rebiotix Recent Developments
- 12.12 Metabiomics
- 12.12.1 Metabiomics Company Information
- 12.12.2 Metabiomics Business Overview
- 12.12.3 Metabiomics Revenue in Microbiome Drugs Business (2021-2026)
- 12.12.4 Metabiomics Microbiome Drugs Product Portfolio
- 12.12.5 Metabiomics Recent Developments
- 12.13 Ritter Pharmaceuticals
- 12.13.1 Ritter Pharmaceuticals Company Information
- 12.13.2 Ritter Pharmaceuticals Business Overview
- 12.13.3 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2021-2026)
- 12.13.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
- 12.13.5 Ritter Pharmaceuticals Recent Developments
- 12.14 Symberix
- 12.14.1 Symberix Company Information
- 12.14.2 Symberix Business Overview
- 12.14.3 Symberix Revenue in Microbiome Drugs Business (2021-2026)
- 12.14.4 Symberix Microbiome Drugs Product Portfolio
- 12.14.5 Symberix Recent Developments
- 12.15 OpenBiome
- 12.15.1 OpenBiome Company Information
- 12.15.2 OpenBiome Business Overview
- 12.15.3 OpenBiome Revenue in Microbiome Drugs Business (2021-2026)
- 12.15.4 OpenBiome Microbiome Drugs Product Portfolio
- 12.15.5 OpenBiome Recent Developments
- 12.16 Azitra
- 12.16.1 Azitra Company Information
- 12.16.2 Azitra Business Overview
- 12.16.3 Azitra Revenue in Microbiome Drugs Business (2021-2026)
- 12.16.4 Azitra Microbiome Drugs Product Portfolio
- 12.16.5 Azitra Recent Developments
- 12.17 Osel
- 12.17.1 Osel Company Information
- 12.17.2 Osel Business Overview
- 12.17.3 Osel Revenue in Microbiome Drugs Business (2021-2026)
- 12.17.4 Osel Microbiome Drugs Product Portfolio
- 12.17.5 Osel Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst